Commercialization of any product involves a long list of procedures like market analysis, patent analysis, patent pending i.e., just a few to mention. For this, every company must have educated special personnel. However, when dealing with biomaterials and medical devices, there are a lot of other issues every company has to do to fulfil the regulation issues required by the authorities.
All potential biological hazards must be considered for every material. Typically, this is done by the company after they have found a promising material suitable to be developed to a product. The documentation of this so called pretoxicological part is time consuming and money demanding. The golden question is; why not to do this during the material development? By a careful project planning a majority of the pretoxicological documentation can be included to the project plan by a research group. The final result of a good planned project is not only a suitable biomaterial developed by the project but also a document file answering to many questions required by the regulation authority. For a potential buyer of the IPR, the existing documentation file shortens the pathway of commercialization for the company and thus, helps researchers in selling of the IPR and increases the price.
At BME, we have expertise in planning of biomaterial and tissue engineering projects in a way which facilitates optimal transfer of university inventions and innovations to commercial products.